Ustekinumabin absoluuttisen biologisen hyötyosuuden arvioitiin olevan psoriaasipotilaille ihon alle annetun kerta- annoksen jälkeen 57, 2%. ###>The absolute bioavailability of ustekinumab following a single subcutaneous administration was estimated to be 57.2% in patients with psoriasis.